{
  "id": 19824047,
  "title": "Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market",
  "url": "https://urgent.news/2026/11/13/pfizer-pulls-menopause-hormone-therapy-premarin-from-canadian-market",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T15:02:02.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/health-care/26/11/63241925/pfizer-pulls-menopause-hormone-therapy-premarin-from-canadian-market"
  },
  "original_language": "en",
  "account": "Pfizer Inc., the U.S. pharmaceutical company, has announced it will discontinue selling its hormone replacement therapy Premarin in Canada due to internal review findings. This decision follows a shortage of the vaginal cream and three oral tablet strengths of Premarin in Canada since June. In a statement to Reuters, Pfizer Canada confirmed that it will no longer distribute Premarin products in the country. The discontinuation of Premarin comes alongside shortages of specific strengths of estradiol transdermal patches, which are also manufactured by Bayer and Sandoz. Health Canada reported that these shortages might lead to strain on Canada's menopause drug supply, with potential shortages persisting until early 2027. Pfizer stated that the decision was not due to safety, efficacy, or quality concerns, but rather internal review findings. The company assured patients that alternative menopause treatment options are still available in Canada. Pfizer's Canadian inventory of the oral tablet strengths (0.3 mg, 0.625 mg, and 1.25 mg) is expected to last until approximately mid-2027, but could run out sooner if demand increases. The discontinuation of Premarin in Canada does not affect the hospital-use formulation, Premarin Intravenous, which treats abnormal uterine bleeding due to hormonal imbalance. Pfizer shares were up 0.31% at $28.92 during premarket trading on Friday.",
  "summary": "Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its vaginal cream and three oral tablet strengths . Pfizer Canada confirmed to Reuters on Thursday that it will supply no further batches of Premarin vaginal cream, which treats menopause symptoms and has experienced shortages…",
  "key_points": [
    "Pfizer discontinues selling Premarin in Canada due to internal review findings.",
    "Vaginal cream and three oral tablet strengths of Premarin face shortages in Canada since June.",
    "Alternative menopause treatments remain available in Canada."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}